|
Volumn 71, Issue 5, 2004, Pages 433-437
|
Six strategies to identify and assist patients burdened by out-of-pocket prescription costs
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
ATORVASTATIN;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CELECOXIB;
CITALOPRAM;
CYCLOOXYGENASE 2 INHIBITOR;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
FLUOXETINE;
GENERIC DRUG;
HYDROCHLOROTHIAZIDE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
IBUPROFEN;
LANSOPRAZOLE;
LISINOPRIL;
LOSARTAN POTASSIUM;
METOPROLOL SUCCINATE;
MEVINOLIN;
NAPROXEN;
NIFEDIPINE;
NONSTEROID ANTIINFLAMMATORY AGENT;
OMEPRAZOLE;
PAROXETINE;
PRAVASTATIN;
RANITIDINE;
ROFECOXIB;
SIMVASTATIN;
UNINDEXED DRUG;
COST BENEFIT ANALYSIS;
COST CONTROL;
DRUG COST;
DRUG EFFICACY;
DRUG USE;
HEALTH CARE FINANCING;
HUMAN;
HYPERTENSION;
PRESCRIPTION;
REVIEW;
SIDE EFFECT;
|
EID: 3042632038
PISSN: 08911150
EISSN: None
Source Type: Journal
DOI: 10.3949/ccjm.71.5.433 Document Type: Review |
Times cited : (30)
|
References (6)
|